Journal of Clinical Practice and Medical Case Report · Oct 14, 2026

Conventional Hormonal Therapy versus Emerging Regenerative Interventions for Genitourinary Syndrome of Menopause: A Technical Comparative Matrix and Evidence-Tiered Feasibility Analysis of 2024–2026 Systematic Reviews and Meta-Analyses

By Kume MH

Background: Genitourinary syndrome of menopause (GSM) affects between 13% and 87% of postmenopausal women depending on ascertainment method, with vaginal dryness reported by 47-100% and dyspareunia by 20-77.6% of symptomatic cohorts [1,10].Lowdose vaginal estrogen and vaginal dehydroepiandrosterone (DHEA, prasterone) are the established pharmacological standards, while energy-based devices (fractional microablative CO2 laser, non-ablative Er:YAG laser, radiofrequency) and platelet-rich plasma (PRP) are marketed as regenerative alternatives.Clinicians therefore face a decision problem in which biological plausibility, surrogate-endpoint responsiveness and controlled clinical benefit diverge.

doi.org/10.52793/jcpmcr.2026.3(1)-38Open accessInterventions

AgingResearch.News